PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.
8pyDTZ is a pyridyl diphenylterazine (DTZ) analog and an ATP-independent pyridyl substrate of LumiLuc luciferase. 8pyDTZ exhibits spectrally shifted emission and improved water solubility. It can be used for in vivo luminescence imaging.
The peak excitation and emission wavelengths of EC-17 are 470 520 nm.EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum.
MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs). MK-6240 exhibits high specificity and selectivity for binding to NFTs.
L-FMAC F-18 has potential diagnostic activity during positron emission tomography (PET) imaging. After phosphorylation by DCK, the 18F moiety can be visualized by PET imaging.